APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Second-Generation Antipsychotics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Second-Generation Antipsychotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174034400323 December 2025190 pages

Choose your research edition.

Industry ResearchSecond-Generation Antipsychotics Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Second-Generation Antipsychotics Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Second-Generation Antipsychotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Second-Generation Antipsychotics Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Second-Generation Antipsychotics Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Second-Generation Antipsychotics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Second-Generation Antipsychotics include Chia Tai Tianqing Pharmaceutical, Yangtze River Pharmaceutical Group, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Novartis, Merck, Luye Pharma Group, Roche and Livzon Pharmaceutical Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Second-Generation Antipsychotics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Second-Generation Antipsychotics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Second-Generation Antipsychotics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Second-Generation Antipsychotics market size, projected growth trends, production technologies, key applications, and end-use industries.

Second-Generation Antipsychotics Segment by Company

Chia Tai Tianqing Pharmaceutical

Yangtze River Pharmaceutical Group

CSPC Pharmaceutical Group

Qilu Pharmaceutical

Novartis

Merck

Luye Pharma Group

Roche

Livzon Pharmaceutical Group

Eli Lilly

Chengdu Kanghong Pharmaceutical

Pfizer

Hansoh Pharma

Hisun Pharmaceutical

Nhwa Pharmaceutical

AbbVie

Sumitomo Dainippon Pharma

Otsuka Pharmaceutical

Johnson And Johnson

Ipsen

Second-Generation Antipsychotics Segment by Type

Selective Dopamine Receptor Antagonists

Multi Receptor Acting Drugs

Dopamine Receptor Partial Agonists

5-Hydroxytryptamine And Dopamine Receptor Antagonists

Second-Generation Antipsychotics Segment by Application

Adjuvant Treatment For Depression

Bipolar Disorder

Schizophrenia

Other Mental Illnesses

Second-Generation Antipsychotics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Second-Generation Antipsychotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Second-Generation Antipsychotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Second-Generation Antipsychotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Second-Generation Antipsychotics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Second-Generation Antipsychotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Second-Generation Antipsychotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Second-Generation Antipsychotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Second-Generation Antipsychotics Industry Trends Table 2. Second-Generation Antipsychotics Industry Drivers Table 3. Second-Generation Antipsychotics Industry Opportunities and Challenges Table 4. Second-Generation Antipsychotics Industry Restraints Table 5. Global Second-Generation Antipsychotics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Second-Generation Antipsychotics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Second-Generation Antipsychotics Sales by Manufacturers (units) & (2021-2026) Table 8. Global Second-Generation Antipsychotics Sales Market Share by Manufacturers Table 9. Global Second-Generation Antipsychotics Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Second-Generation Antipsychotics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Second-Generation Antipsychotics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Second-Generation Antipsychotics Manufacturers, Product Type & Application Table 13. Global Second-Generation Antipsychotics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Second-Generation Antipsychotics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Selective Dopamine Receptor Antagonists Table 17. Major Manufacturers of Multi Receptor Acting Drugs Table 18. Major Manufacturers of Dopamine Receptor Partial Agonists Table 19. Major Manufacturers of 5-Hydroxytryptamine And Dopamine Receptor Antagonists Table 20. Global Second-Generation Antipsychotics Sales by Type 2021 VS 2025 VS 2032 (units) Table 21. Global Second-Generation Antipsychotics Sales by Type (2021-2026) & (units) Table 22. Global Second-Generation Antipsychotics Sales by Type (2027-2032) & (units) Table 23. Global Second-Generation Antipsychotics Sales Market Share by Type (2021-2026) Table 24. Global Second-Generation Antipsychotics Sales Market Share by Type (2027-2032) Table 25. Global Second-Generation Antipsychotics Revenue by Type 2021 VS 2025 VS 2032 (units) Table 26. Global Second-Generation Antipsychotics Revenue by Type (2021-2026) & (units) Table 27. Global Second-Generation Antipsychotics Revenue by Type (2027-2032) & (units) Table 28. Global Second-Generation Antipsychotics Revenue Market Share by Type (2021-2026) Table 29. Global Second-Generation Antipsychotics Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Adjuvant Treatment For Depression Table 31. Major Manufacturers of Bipolar Disorder Table 32. Major Manufacturers of Schizophrenia Table 33. Major Manufacturers of Other Mental Illnesses Table 34. Global Second-Generation Antipsychotics Sales by Application 2021 VS 2025 VS 2032 (units) Table 35. Global Second-Generation Antipsychotics Sales by Application (2021-2026) & (units) Table 36. Global Second-Generation Antipsychotics Sales by Application (2027-2032) & (units) Table 37. Global Second-Generation Antipsychotics Sales Market Share by Application (2021-2026) Table 38. Global Second-Generation Antipsychotics Sales Market Share by Application (2027-2032) Table 39. Global Second-Generation Antipsychotics Revenue by Application 2021 VS 2025 VS 2032 (units) Table 40. Global Second-Generation Antipsychotics Revenue by Application (2021-2026) & (units) Table 41. Global Second-Generation Antipsychotics Revenue by Application (2027-2032) & (units) Table 42. Global Second-Generation Antipsychotics Revenue Market Share by Application (2021-2026) Table 43. Global Second-Generation Antipsychotics Revenue Market Share by Application (2027-2032) Table 44. Global Second-Generation Antipsychotics Sales by Region: 2021 VS 2025 VS 2032 (units) Table 45. Global Second-Generation Antipsychotics Sales by Region (2021-2026) & (units) Table 46. Global Second-Generation Antipsychotics Sales Market Share by Region (2021-2026) Table 47. Global Second-Generation Antipsychotics Sales Forecasted by Region (2027-2032) & (units) Table 48. Global Second-Generation Antipsychotics Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 50. North America Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 51. North America Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 52. Europe Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 53. Europe Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 54. Europe Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 55. Asia Pacific Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 56. Asia Pacific Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 57. Asia Pacific Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 58. South America, Middle East and Africa Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 59. South America, Middle East and Africa Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 60. South America, Middle East and Africa Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 61. Global Second-Generation Antipsychotics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Second-Generation Antipsychotics Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Second-Generation Antipsychotics Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Second-Generation Antipsychotics Revenue Market Share by Region (2021-2026) Table 65. Global Second-Generation Antipsychotics Revenue Market Share by Region (2027-2032) Table 66. Chia Tai Tianqing Pharmaceutical Company Information Table 67. Chia Tai Tianqing Pharmaceutical Business Overview Table 68. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 70. Chia Tai Tianqing Pharmaceutical Recent Development Table 71. Yangtze River Pharmaceutical Group Company Information Table 72. Yangtze River Pharmaceutical Group Business Overview Table 73. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 75. Yangtze River Pharmaceutical Group Recent Development Table 76. CSPC Pharmaceutical Group Company Information Table 77. CSPC Pharmaceutical Group Business Overview Table 78. CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 80. CSPC Pharmaceutical Group Recent Development Table 81. Qilu Pharmaceutical Company Information Table 82. Qilu Pharmaceutical Business Overview Table 83. Qilu Pharmaceutical Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 85. Qilu Pharmaceutical Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Novartis Second-Generation Antipsychotics Product Portfolio Table 90. Novartis Recent Development Table 91. Merck Company Information Table 92. Merck Business Overview Table 93. Merck Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Merck Second-Generation Antipsychotics Product Portfolio Table 95. Merck Recent Development Table 96. Luye Pharma Group Company Information Table 97. Luye Pharma Group Business Overview Table 98. Luye Pharma Group Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Luye Pharma Group Second-Generation Antipsychotics Product Portfolio Table 100. Luye Pharma Group Recent Development Table 101. Roche Company Information Table 102. Roche Business Overview Table 103. Roche Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Roche Second-Generation Antipsychotics Product Portfolio Table 105. Roche Recent Development Table 106. Livzon Pharmaceutical Group Company Information Table 107. Livzon Pharmaceutical Group Business Overview Table 108. Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 110. Livzon Pharmaceutical Group Recent Development Table 111. Eli Lilly Company Information Table 112. Eli Lilly Business Overview Table 113. Eli Lilly Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Eli Lilly Second-Generation Antipsychotics Product Portfolio Table 115. Eli Lilly Recent Development Table 116. Chengdu Kanghong Pharmaceutical Company Information Table 117. Chengdu Kanghong Pharmaceutical Business Overview Table 118. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 120. Chengdu Kanghong Pharmaceutical Recent Development Table 121. Pfizer Company Information Table 122. Pfizer Business Overview Table 123. Pfizer Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Pfizer Second-Generation Antipsychotics Product Portfolio Table 125. Pfizer Recent Development Table 126. Hansoh Pharma Company Information Table 127. Hansoh Pharma Business Overview Table 128. Hansoh Pharma Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Hansoh Pharma Second-Generation Antipsychotics Product Portfolio Table 130. Hansoh Pharma Recent Development Table 131. Hisun Pharmaceutical Company Information Table 132. Hisun Pharmaceutical Business Overview Table 133. Hisun Pharmaceutical Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 135. Hisun Pharmaceutical Recent Development Table 136. Nhwa Pharmaceutical Company Information Table 137. Nhwa Pharmaceutical Business Overview Table 138. Nhwa Pharmaceutical Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 140. Nhwa Pharmaceutical Recent Development Table 141. AbbVie Company Information Table 142. AbbVie Business Overview Table 143. AbbVie Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. AbbVie Second-Generation Antipsychotics Product Portfolio Table 145. AbbVie Recent Development Table 146. Sumitomo Dainippon Pharma Company Information Table 147. Sumitomo Dainippon Pharma Business Overview Table 148. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio Table 150. Sumitomo Dainippon Pharma Recent Development Table 151. Otsuka Pharmaceutical Company Information Table 152. Otsuka Pharmaceutical Business Overview Table 153. Otsuka Pharmaceutical Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 155. Otsuka Pharmaceutical Recent Development Table 156. Johnson And Johnson Company Information Table 157. Johnson And Johnson Business Overview Table 158. Johnson And Johnson Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Johnson And Johnson Second-Generation Antipsychotics Product Portfolio Table 160. Johnson And Johnson Recent Development Table 161. Ipsen Company Information Table 162. Ipsen Business Overview Table 163. Ipsen Second-Generation Antipsychotics Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Ipsen Second-Generation Antipsychotics Product Portfolio Table 165. Ipsen Recent Development Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Second-Generation Antipsychotics Distributors List Table 169. Second-Generation Antipsychotics Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Second-Generation Antipsychotics Product Image Figure 2. Global Second-Generation Antipsychotics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Second-Generation Antipsychotics Market Size (2021-2032) & (US$ Million) Figure 4. Global Second-Generation Antipsychotics Sales (2021-2032) & (units) Figure 5. Global Second-Generation Antipsychotics Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Second-Generation Antipsychotics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Selective Dopamine Receptor Antagonists Image Figure 9. Multi Receptor Acting Drugs Image Figure 10. Dopamine Receptor Partial Agonists Image Figure 11. 5-Hydroxytryptamine And Dopamine Receptor Antagonists Image Figure 12. Global Second-Generation Antipsychotics Sales by Type (2021 VS 2025 VS 2032) & (units) Figure 13. Global Second-Generation Antipsychotics Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Second-Generation Antipsychotics Sales Market Share by Type (2021-2032) Figure 15. Global Second-Generation Antipsychotics Revenue by Type (2021 VS 2025 VS 2032) & (units) Figure 16. Global Second-Generation Antipsychotics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Second-Generation Antipsychotics Revenue Market Share by Type (2021-2032) Figure 18. Adjuvant Treatment For Depression Image Figure 19. Bipolar Disorder Image Figure 20. Schizophrenia Image Figure 21. Other Mental Illnesses Image Figure 22. Global Second-Generation Antipsychotics Sales by Application (2021 VS 2025 VS 2032) & (units) Figure 23. Global Second-Generation Antipsychotics Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Second-Generation Antipsychotics Sales Market Share by Application (2021-2032) Figure 25. Global Second-Generation Antipsychotics Revenue by Application (2021 VS 2025 VS 2032) & (units) Figure 26. Global Second-Generation Antipsychotics Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Second-Generation Antipsychotics Revenue Market Share by Application (2021-2032) Figure 28. North America Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 29. North America Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 30. U.S. Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 31. Canada Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 32. Mexico Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 33. Europe Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 34. Europe Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 35. Germany Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 36. France Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 37. U.K. Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 38. Italy Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 39. Netherlands Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 40. Asia Pacific Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 41. Asia Pacific Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 42. China Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 43. Japan Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 44. South Korea Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 45. Southeast Asia Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 46. India Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 47. Australia Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 48. South America, Middle East and Africa Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 49. South America, Middle East and Africa Second-Generation Antipsychotics Sales Market Share by Country (2021-2032) Figure 50. Brazil Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 51. South Africa Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 52. Saudi Arabia Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 53. Turkey Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 54. Argentina Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 55. UAE Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 56. Egypt Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 57. Chile Second-Generation Antipsychotics Sales and Growth Rate (2021-2032) & (units) Figure 58. Global Second-Generation Antipsychotics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Second-Generation Antipsychotics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Second-Generation Antipsychotics Revenue (2021-2032) & (US$ Million) Figure 61. North America Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Second-Generation Antipsychotics Revenue (2021-2032) & (US$ Million) Figure 63. Europe Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Second-Generation Antipsychotics Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Second-Generation Antipsychotics Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Second-Generation Antipsychotics Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Second-Generation Antipsychotics Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Selective Dopamine Receptor Antagonists
  • Multi Receptor Acting Drugs
  • Dopamine Receptor Partial Agonists
  • 5-Hydroxytryptamine And Dopamine Receptor Antagonists
Applications
  • Adjuvant Treatment For Depression
  • Bipolar Disorder
  • Schizophrenia
  • Other Mental Illnesses
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yangtze River Pharmaceutical Group
  • CSPC Pharmaceutical Group
  • Qilu Pharmaceutical
  • Novartis
  • Merck
  • Luye Pharma Group
  • Roche
  • Livzon Pharmaceutical Group
  • Eli Lilly
  • Chengdu Kanghong Pharmaceutical
  • Pfizer
  • Hansoh Pharma
  • Hisun Pharmaceutical
  • Nhwa Pharmaceutical
  • AbbVie
  • Sumitomo Dainippon Pharma
  • Otsuka Pharmaceutical
  • Johnson And Johnson
  • Ipsen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Second-Generation Antipsychotics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Second-Generation Antipsychotics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Second-Generation Antipsychotics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Second-Generation Antipsychotics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Second-Generation Antipsychotics Market Dynamics
  1. 2.1 Second-Generation Antipsychotics Industry Trends
  2. 2.2 Second-Generation Antipsychotics Industry Drivers
  3. 2.3 Second-Generation Antipsychotics Industry Opportunities and Challenges
  4. 2.4 Second-Generation Antipsychotics Industry Restraints
3 Second-Generation Antipsychotics Market by Manufacturers
  1. 3.1 Global Second-Generation Antipsychotics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Second-Generation Antipsychotics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Second-Generation Antipsychotics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Second-Generation Antipsychotics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Second-Generation Antipsychotics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Second-Generation Antipsychotics Manufacturers, Product Type & Application
  7. 3.7 Global Second-Generation Antipsychotics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Second-Generation Antipsychotics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Second-Generation Antipsychotics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Second-Generation Antipsychotics Tier 1, Tier 2, and Tier 3
4 Second-Generation Antipsychotics Market by Type
  1. 4.1 Second-Generation Antipsychotics Type Introduction
  2. 4.1.1 Selective Dopamine Receptor Antagonists
  3. 4.1.2 Multi Receptor Acting Drugs
  4. 4.1.3 Dopamine Receptor Partial Agonists
  5. 4.1.4 5-Hydroxytryptamine And Dopamine Receptor Antagonists
  6. 4.2 Global Second-Generation Antipsychotics Sales by Type
  7. 4.2.1 Global Second-Generation Antipsychotics Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Second-Generation Antipsychotics Sales by Type (2021-2032)
  9. 4.2.3 Global Second-Generation Antipsychotics Sales Market Share by Type (2021-2032)
  10. 4.3 Global Second-Generation Antipsychotics Revenue by Type
  11. 4.3.1 Global Second-Generation Antipsychotics Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Second-Generation Antipsychotics Revenue by Type (2021-2032)
  13. 4.3.3 Global Second-Generation Antipsychotics Revenue Market Share by Type (2021-2032)
5 Second-Generation Antipsychotics Market by Application
  1. 5.1 Second-Generation Antipsychotics Application Introduction
  2. 5.1.1 Adjuvant Treatment For Depression
  3. 5.1.2 Bipolar Disorder
  4. 5.1.3 Schizophrenia
  5. 5.1.4 Other Mental Illnesses
  6. 5.2 Global Second-Generation Antipsychotics Sales by Application
  7. 5.2.1 Global Second-Generation Antipsychotics Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Second-Generation Antipsychotics Sales by Application (2021-2032)
  9. 5.2.3 Global Second-Generation Antipsychotics Sales Market Share by Application (2021-2032)
  10. 5.3 Global Second-Generation Antipsychotics Revenue by Application
  11. 5.3.1 Global Second-Generation Antipsychotics Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Second-Generation Antipsychotics Revenue by Application (2021-2032)
  13. 5.3.3 Global Second-Generation Antipsychotics Revenue Market Share by Application (2021-2032)
6 Global Second-Generation Antipsychotics Sales by Region
  1. 6.1 Global Second-Generation Antipsychotics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Second-Generation Antipsychotics Sales by Region (2021-2032)
  3. 6.2.1 Global Second-Generation Antipsychotics Sales by Region (2021-2026)
  4. 6.2.2 Global Second-Generation Antipsychotics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Second-Generation Antipsychotics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Second-Generation Antipsychotics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Second-Generation Antipsychotics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Second-Generation Antipsychotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Second-Generation Antipsychotics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Second-Generation Antipsychotics Revenue by Region
  1. 7.1 Global Second-Generation Antipsychotics Revenue by Region
  2. 7.1.1 Global Second-Generation Antipsychotics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Second-Generation Antipsychotics Revenue by Region (2021-2026)
  4. 7.1.3 Global Second-Generation Antipsychotics Revenue by Region (2027-2032)
  5. 7.1.4 Global Second-Generation Antipsychotics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Second-Generation Antipsychotics Revenue (2021-2032)
  8. 7.2.2 North America Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Second-Generation Antipsychotics Revenue (2021-2032)
  11. 7.3.2 Europe Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Second-Generation Antipsychotics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Second-Generation Antipsychotics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Second-Generation Antipsychotics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Yangtze River Pharmaceutical Group
  8. 8.2.1 Yangtze River Pharmaceutical Group Company Information
  9. 8.2.2 Yangtze River Pharmaceutical Group Business Overview
  10. 8.2.3 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  12. 8.2.5 Yangtze River Pharmaceutical Group Recent Developments
  13. 8.3 CSPC Pharmaceutical Group
  14. 8.3.1 CSPC Pharmaceutical Group Company Information
  15. 8.3.2 CSPC Pharmaceutical Group Business Overview
  16. 8.3.3 CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  18. 8.3.5 CSPC Pharmaceutical Group Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Second-Generation Antipsychotics Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Second-Generation Antipsychotics Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Luye Pharma Group
  38. 8.7.1 Luye Pharma Group Company Information
  39. 8.7.2 Luye Pharma Group Business Overview
  40. 8.7.3 Luye Pharma Group Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Luye Pharma Group Second-Generation Antipsychotics Product Portfolio
  42. 8.7.5 Luye Pharma Group Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Second-Generation Antipsychotics Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Livzon Pharmaceutical Group
  50. 8.9.1 Livzon Pharmaceutical Group Company Information
  51. 8.9.2 Livzon Pharmaceutical Group Business Overview
  52. 8.9.3 Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  54. 8.9.5 Livzon Pharmaceutical Group Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Second-Generation Antipsychotics Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Chengdu Kanghong Pharmaceutical
  62. 8.11.1 Chengdu Kanghong Pharmaceutical Company Information
  63. 8.11.2 Chengdu Kanghong Pharmaceutical Business Overview
  64. 8.11.3 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  66. 8.11.5 Chengdu Kanghong Pharmaceutical Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Second-Generation Antipsychotics Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 Hansoh Pharma
  74. 8.13.1 Hansoh Pharma Company Information
  75. 8.13.2 Hansoh Pharma Business Overview
  76. 8.13.3 Hansoh Pharma Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hansoh Pharma Second-Generation Antipsychotics Product Portfolio
  78. 8.13.5 Hansoh Pharma Recent Developments
  79. 8.14 Hisun Pharmaceutical
  80. 8.14.1 Hisun Pharmaceutical Company Information
  81. 8.14.2 Hisun Pharmaceutical Business Overview
  82. 8.14.3 Hisun Pharmaceutical Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  84. 8.14.5 Hisun Pharmaceutical Recent Developments
  85. 8.15 Nhwa Pharmaceutical
  86. 8.15.1 Nhwa Pharmaceutical Company Information
  87. 8.15.2 Nhwa Pharmaceutical Business Overview
  88. 8.15.3 Nhwa Pharmaceutical Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  90. 8.15.5 Nhwa Pharmaceutical Recent Developments
  91. 8.16 AbbVie
  92. 8.16.1 AbbVie Company Information
  93. 8.16.2 AbbVie Business Overview
  94. 8.16.3 AbbVie Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AbbVie Second-Generation Antipsychotics Product Portfolio
  96. 8.16.5 AbbVie Recent Developments
  97. 8.17 Sumitomo Dainippon Pharma
  98. 8.17.1 Sumitomo Dainippon Pharma Company Information
  99. 8.17.2 Sumitomo Dainippon Pharma Business Overview
  100. 8.17.3 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio
  102. 8.17.5 Sumitomo Dainippon Pharma Recent Developments
  103. 8.18 Otsuka Pharmaceutical
  104. 8.18.1 Otsuka Pharmaceutical Company Information
  105. 8.18.2 Otsuka Pharmaceutical Business Overview
  106. 8.18.3 Otsuka Pharmaceutical Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  108. 8.18.5 Otsuka Pharmaceutical Recent Developments
  109. 8.19 Johnson And Johnson
  110. 8.19.1 Johnson And Johnson Company Information
  111. 8.19.2 Johnson And Johnson Business Overview
  112. 8.19.3 Johnson And Johnson Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Johnson And Johnson Second-Generation Antipsychotics Product Portfolio
  114. 8.19.5 Johnson And Johnson Recent Developments
  115. 8.20 Ipsen
  116. 8.20.1 Ipsen Company Information
  117. 8.20.2 Ipsen Business Overview
  118. 8.20.3 Ipsen Second-Generation Antipsychotics Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Ipsen Second-Generation Antipsychotics Product Portfolio
  120. 8.20.5 Ipsen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Second-Generation Antipsychotics Value Chain Analysis
  2. 9.1.1 Second-Generation Antipsychotics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Second-Generation Antipsychotics Production Mode & Process
  6. 9.2 Second-Generation Antipsychotics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Second-Generation Antipsychotics Distributors
  9. 9.2.3 Second-Generation Antipsychotics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst